Images List Premium Download Classic

Dysfunction

Dysfunction-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Dna array for detecting canine toll-like receptor gene mutations
Crag-centre De Recerca En Agrigenòmica
August 17, 2017 - N°20170233811

Dna array for detecting canine toll-like receptor gene mutations new mutations in canine toll-like receptor genes are provided. The invention relates further to dna arrays comprising oligonucleotides capable of hybridizing to at least a tlr gene fragment codifying for at least one of the new mutations leading to non-functional proteins. The invention also includes methods for the analysis of mutations ...
Tetrahydroisoquinoline derivatives
Cytokinetics, Incorporated
August 17, 2017 - N°20170233402

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast ...
Compounds, compositions, and methods for increasing cftr activity
Proteostasis Therapeutics, Inc.
August 17, 2017 - N°20170233379

The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (cftr) activity as measured in human bronchial epithelial (hbe) cells. The present disclosure also features methods of treating a condition associated with decreased cftr activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for the treatment of retinal degeneration
Universite De Strasbourg
August 17, 2017 - N°20170231930

The present invention relates to a pharmaceutical composition comprising an inhibitor of eif2α, a compound increasing the expression and/or activity of protein bip and/or an inhibitor of caspase-12, preferably an inhibitor of eif2α and a compound increasing the expression and/or activity of protein bip. The present invention also relates to pharmaceutical compositions and ...
Limb treatment device and method for treatment of vascular and/or neuropathic disorders
Universite De Strasbourg
August 17, 2017 - N°20170231858

A medical treatment device and method provide relief from symptoms of peripheral neuropathy and/or vascular dysfunction. The device provides pressure along an inner surface of a human limb of a user, so that at least a portion of the pressure is derived from the weight of the user seated atop the device, and includes a frame for providing support ...
Apparatus and methods for screening patients for bladder control via pudendal nerve stimulation
Incube Labs, Llc
August 17, 2017 - N°20170231547

Embodiments of the invention provide apparatus and methods for testing the efficacy of nerve stimulation therapy to treat patients who have urinary dysfunction prior to the implantation of an apparatus to treat the dysfunction. The apparatus and methods provide means to selectively stimulate the pudendal nerve with high and low frequency current to produce a physiologic response involved in the ...
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
Immunomedics, Inc.
August 10, 2017 - N°20170226205

Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may ...
Subcutaneous administration of adamts13
Baxalta Gmbh
August 10, 2017 - N°20170224785

This invention relates to methods of subcutaneous administration of adamts13 formulations to a treat a disease or condition associated with adamts13 and vwf dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of adamts13 formulations administered subcutaneously is provided herein.
Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
University Of Maryland, Baltimore
August 10, 2017 - N°20170224779

The present invention generally to methods of treating subjects suffering from a cardiac condition or having a risk factor for developing a cardiac condition by administering an ela peptide or fusion protein to a subject in need. The invention relates to fusion proteins of fc-ela-32 and fc-ela-21 that exhibit improved properties for use as therapeutic agents, e. G. In the ...
Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
University Of Maryland, Baltimore
August 10, 2017 - N°20170224633

Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for ...
Method to treat vascular dysfunction through enhanced vascular flow and hemodynamic activation of the autocrine ...
University Of Maryland, Baltimore
August 03, 2017 - N°20170216591

A method and system for creating shear stress and endothelial mechanotransduction through neuromuscular stimulation of the muscle pump. Chronic application a minimum of 30 days triggers the autocrine and paracrine processes which elevates production of vasoactive substances including nitric oxide, prostacyclin, superoxide dismutase, thrombomodulin, glutathion, krupple-like factor 2 and many others. Chronic application also promotes angiogenesis and development of collateral circulation. This ...
Methods for the prevention and treatment of burn injuries and secondary complications
The General Hospital Corporation D/b/a Massachusetts General Hospital
August 03, 2017 - N°20170216394

The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject ...
Vaginal inserted estradiol pharmaceutical compositions and methods
Therapeuticsmd, Inc.
August 03, 2017 - N°20170216310

Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (vva) and female sexual dysfunction (fsd).
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sildenafil sublingual spray formulations
Insys Development Company, Inc.
August 03, 2017 - N°20170216196

The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.
Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
July 27, 2017 - N°20170209495

The present invention provides muscle-derived progenitor cells (mdcs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating mdcs. The invention further provides methods of using compositions comprising mdcs for the augmentation and bulking of mammalian, including human, soft tissues in ...
Use of adelmidrol in the treatment of epithelial dysfunctions
Epitech Group S.r.l.
July 27, 2017 - N°20170209395

Described herein is the use of adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said adelmidrol causes an increase of the endogenous levels of palmitoylethanolamide without inhibiting the activity of the palmitoylethanolamide-degrading faah and naaa enzymes.
Hand-held optical scanner for real-time imaging of body composition and metabolism
The Regents Of The University Of California
July 27, 2017 - N°20170209083

A low cost portable high speed quantitative system for diffuse optical spectroscopic imaging of human tissue. The hybrid system (cwfd) can measure absolute optical properties from 660 nm to 980 nm and recover all tissue chromophore concentrations. The standalone fd module can be utilized to measure scattering at every measurement and recover deoxygenated and oxygenated hemoglobin concentrations. The cw module can operate ...
Language element vision augmentation methods and devices
Esight Corp.
July 13, 2017 - N°20170200296

Near-to-eye displays support a range of applications from helping users with low vision through augmenting a real world view to displaying virtual environments. The images displayed may contain text to be read by the user. It would be beneficial to provide users with text enhancements to improve its readability and legibility, as measured through improved reading speed and/or comprehension. ...
2-acylaminothiazole derivative or salt thereof
Esight Corp.
July 13, 2017 - N°20170197955

The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic m3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic m3 receptor, thereby completing the present invention. 2-acylaminothiazole derivative or a salt thereof of the present ...
Allosteric modulators of cb1 cannabinoid receptors
Northeastern University
July 13, 2017 - N°20170197918

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of ...
Treatment for tumors driven by metabolic dysfunction
Syndevrx, Inc.
July 13, 2017 - N°20170196830

The present disclosure relates to modified or polymer conjugated metap2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
Loading